Jeffrey Davis

Subscribe to Jeffrey Davis's Posts

Jeffrey is a skilled healthcare executive with substantial knowledge of regulatory advocacy and healthcare policies. Jeffrey’s work focuses on issues tied to provider payment and reimbursement as well as quality reporting. He also has significant experience with recent regulatory developments such as the implementation of surprise billing rules. Read Jeffrey Davis's full bio.

Surprise Billing Arbitration Is Still a Mess

By Jeffrey Davis on Nov 22, 2023
Posted In Employee Benefits, Health and Welfare Plans

Despite a two-year-old ban on surprise medical billing, insurers and providers are struggling to resolve unpaid claims. In this Axios article, McDermott+Consulting’s Jeffrey Davis offers perspective on the state of the claims resolution process. Read more here.

Continue Reading

Patients May Not Feel Benefits of Medicare Drug Price Negotiations

By Jeffrey Davis on Oct 4, 2023
Posted In Employee Benefits, Health and Welfare Plans, Uncategorized

The Biden administration recently announced a list of Medicare-covered drugs that will be subject to price negotiations. The administration said the negotiations—a reality thanks to the Inflation Reduction Act—will benefit nearly nine million seniors. However, according to this Insider article, some drug-policy analysts seem unconvinced by the administration’s claims. Access the article.

Continue Reading